Averon CPP Ltd. Class AF7-2 Rating Placed On CreditWatch Negative Dec 11

  • ID: 2035349
  • December 2011
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) Dec. 29, 2011--Standard & Poor's Ratings Services today placed its 'AAAp NRi' rating on Averon CPP Ltd.'s A$29.4 million series AF7-2 controlled proportion portfolio-linked notes on CreditWatch with negative implications. The rating on the notes is dependent on the rating on the underlying security, Dexia Municipal Agency's series 343 floating-rate obligations fonciere due June 19, 2014 ('AAA/Watch Neg'). Today's CreditWatch placement follows the Dec. 15, 2011, placement of our 'AAA' rating on the underlying security on CreditWatch with negative implications. We may take subsequent rating actions on the notes due to changes in our rating on the underlying security. STANDARD & POOR'S 17G-7 DISCLOSURE REPORT SEC Rule 17g-7 requires an NRSRO, for any report accompanying...

Companies mentioned in this report are:
- Averon CPP Ltd.

Action: On CreditWatch:Negative

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Averon CPP Ltd.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.